Literature DB >> 12183560

Immunogenicity in a mouse model of a conjugate vaccine made with a synthetic single repeating unit of type 14 pneumococcal polysaccharide coupled to CRM197.

Fatme Mawas1, Jutta Niggemann, Christopher Jones, Michael J Corbel, Johannis P Kamerling, Johannes F G Vliegenthart.   

Abstract

Oligosaccharides (OSs) related to the pneumococcal type 14 capsular polysaccharide (Pn14PS) were studied for their ability to inhibit the binding between anti-PS14 antisera and native PS14. A synthetic tetrasaccharide corresponding to the repeating unit of the Pn14PS, a hexasaccharide mimic, and an octasaccharide fragment obtained by Pn14PS depolymerization were good inhibitors. CRM197 conjugates of the tetrasaccharide and an octasaccharide mimic were prepared by using either adipic acid diester or diethyl squarate linkers. The conjugate with the tetrasaccharide chains induced anti-Pn14PS antibodies when injected subcutaneously into mice, as determined by an enzyme-linked immunosorbent assay, and antibody titers increased with oligosaccharide loading. The adipic acid-linked tetrasaccharide conjugates elicited higher antibody titers than those prepared with a squarate spacer. The lower anti-Pn14PS antibody response of the octasaccharide mimic conjugate indicates the importance of the backbone galactose residue for an appropriate antibody response. The OS-CRM197 conjugate prepared from a single repeat unit of the Pn14PS is a potential vaccine candidate.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12183560      PMCID: PMC128223          DOI: 10.1128/IAI.70.9.5107-5114.2002

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  34 in total

1.  Synthetic 6B di-, tri-, and tetrasaccharide-protein conjugates contain pneumococcal type 6A and 6B common and 6B-specific epitopes that elicit protective antibodies in mice.

Authors:  W T Jansen; S Hogenboom; M J Thijssen; J P Kamerling; J F Vliegenthart; J Verhoef; H Snippe; A F Verheul
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

2.  Synthetic polysaccharide type 3-related di-, tri-, and tetrasaccharide-CRM(197) conjugates induce protection against Streptococcus pneumoniae type 3 in mice.

Authors:  B Benaissa-Trouw; D J Lefeber; J P Kamerling; J F Vliegenthart; K Kraaijeveld; H Snippe
Journal:  Infect Immun       Date:  2001-07       Impact factor: 3.441

3.  Immunogenicity of a fucosyl-GM1-keyhole limpet hemocyanin conjugate vaccine in patients with small cell lung cancer.

Authors:  M N Dickler; G Ragupathi; N X Liu; C Musselli; D J Martino; V A Miller; M G Kris; F T Brezicka; P O Livingston; S C Grant
Journal:  Clin Cancer Res       Date:  1999-10       Impact factor: 12.531

4.  Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers.

Authors:  H R Shinefield; S Black; P Ray; I Chang; N Lewis; B Fireman; J Hackell; P R Paradiso; G Siber; R Kohberger; D V Madore; F J Malinowski; A Kimura; C Le; I Landaw; J Aguilar; J Hansen
Journal:  Pediatr Infect Dis J       Date:  1999-09       Impact factor: 2.129

5.  Size fractionation of bacterial capsular polysaccharides for their use in conjugate vaccines.

Authors:  P Costantino; F Norelli; A Giannozzi; S D'Ascenzi; A Bartoloni; S Kaur; D Tang; R Seid; S Viti; R Paffetti; M Bigio; C Pennatini; G Averani; V Guarnieri; E Gallo; N Ravenscroft; C Lazzeroni; R Rappuoli; C Ceccarini
Journal:  Vaccine       Date:  1999-03-05       Impact factor: 3.641

6.  Polyclonal antibodies from patients immunized with a globo H-keyhole limpet hemocyanin vaccine: isolation, quantification, and characterization of immune responses by using totally synthetic immobilized tumor antigens.

Authors:  Z G Wang; L J Williams; X F Zhang; A Zatorski; V Kudryashov; G Ragupathi; M Spassova; W Bornmann; S F Slovin; H I Scher; P O Livingston; K O Lloyd; S J Danishefsky
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-14       Impact factor: 11.205

7.  Vaccines prepared with sialyl-Tn and sialyl-Tn trimers using the 4-(4-maleimidomethyl)cyclohexane-1-carboxyl hydrazide linker group result in optimal antibody titers against ovine submaxillary mucin and sialyl-Tn-positive tumor cells.

Authors:  G Ragupathi; L Howard; S Cappello; R R Koganty; D Qiu; B M Longenecker; M A Reddish; K O Lloyd; P O Livingston
Journal:  Cancer Immunol Immunother       Date:  1999-04       Impact factor: 6.968

8.  Dose dependency of antibody response in infants and children to pneumococcal polysaccharides conjugated to tetanus toxoid.

Authors:  H Ahman; H Käyhty; A Vuorela; O Leroy; J Eskola
Journal:  Vaccine       Date:  1999-06-04       Impact factor: 3.641

9.  Immunogenicity of conjugate vaccines consisting of pneumococcal capsular polysaccharide types 6B, 14, 19F, and 23F and a meningococcal outer membrane protein complex.

Authors:  P P Vella; S Marburg; J M Staub; P J Kniskern; W Miller; A Hagopian; C Ip; R L Tolman; C M Rusk; L S Chupak
Journal:  Infect Immun       Date:  1992-12       Impact factor: 3.441

10.  Carbohydrate vaccines in cancer: immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man.

Authors:  S F Slovin; G Ragupathi; S Adluri; G Ungers; K Terry; S Kim; M Spassova; W G Bornmann; M Fazzari; L Dantis; K Olkiewicz; K O Lloyd; P O Livingston; S J Danishefsky; H I Scher
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-11       Impact factor: 11.205

View more
  22 in total

1.  Conjugate Vaccines from Bacterial Antigens by Squaric Acid Chemistry: A Closer Look.

Authors:  Peng Xu; Meagan Kelly; Willie F Vann; Firdausi Qadri; Edward T Ryan; Pavol Kováč
Journal:  Chembiochem       Date:  2017-03-23       Impact factor: 3.164

2.  The immune response to group B streptococcus type III capsular polysaccharide is directed to the -Glc-GlcNAc-Gal- backbone epitope.

Authors:  Dodi Safari; Huberta A T Dekker; Ger T Rijkers; Arie van der Ende; Johannis P Kamerling; Harm Snippe
Journal:  Glycoconj J       Date:  2011-10-08       Impact factor: 2.916

3.  A semisynthetic Streptococcus pneumoniae serotype 8 glycoconjugate vaccine.

Authors:  Benjamin Schumann; Heung Sik Hahm; Sharavathi G Parameswarappa; Katrin Reppe; Annette Wahlbrink; Subramanian Govindan; Paulina Kaplonek; Liise-Anne Pirofski; Martin Witzenrath; Chakkumkal Anish; Claney L Pereira; Peter H Seeberger
Journal:  Sci Transl Med       Date:  2017-03-08       Impact factor: 17.956

4.  Chemical synthesis of the outer core oligosaccharide of Escherichia coli R3 and immunological evaluation.

Authors:  Wenjing Shang; Zhongying Xiao; Zaikuan Yu; Na Wei; Guohui Zhao; Qing Zhang; Mohui Wei; Xuan Wang; Peng George Wang; Tiehai Li
Journal:  Org Biomol Chem       Date:  2015-03-12       Impact factor: 3.876

5.  Synthetic and immunological studies of 5'-N-phenylacetyl sTn to develop carbohydrate-based cancer vaccines and to explore the impacts of linkage between carbohydrate antigens and carrier proteins.

Authors:  Qianli Wang; Sandamali Amarasingha Ekanayaka; Jian Wu; Junping Zhang; Zhongwu Guo
Journal:  Bioconjug Chem       Date:  2008-09-25       Impact factor: 4.774

6.  Identification of the smallest structure capable of evoking opsonophagocytic antibodies against Streptococcus pneumoniae type 14.

Authors:  Dodi Safari; Huberta A T Dekker; John A F Joosten; Dirk Michalik; Adriana Carvalho de Souza; Roberto Adamo; Martina Lahmann; Andreas Sundgren; Stefan Oscarson; Johannis P Kamerling; Harm Snippe
Journal:  Infect Immun       Date:  2008-08-04       Impact factor: 3.441

7.  Saccharide/protein conjugate vaccines for Bordetella species: preparation of saccharide, development of new conjugation procedures, and physico-chemical and immunological characterization of the conjugates.

Authors:  Joanna Kubler-Kielb; Evgeny Vinogradov; Gil Ben-Menachem; Vince Pozsgay; John B Robbins; Rachel Schneerson
Journal:  Vaccine       Date:  2008-05-20       Impact factor: 3.641

8.  Preparation of glycoconjugates by dialkyl squarate chemistry revisited.

Authors:  Shu-Jie Hou; Rina Saksena; Pavol Kovác
Journal:  Carbohydr Res       Date:  2007-10-26       Impact factor: 2.104

9.  Synthetic glycopeptide vaccines combining beta-mannan and peptide epitopes induce protection against candidiasis.

Authors:  Hong Xin; Sebastian Dziadek; David R Bundle; Jim E Cutler
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-25       Impact factor: 11.205

10.  Facile preparation of fluorescent neoglycoproteins using p-nitrophenyl anthranilate as a heterobifunctional linker.

Authors:  Anthony Luyai; Yi Lasanajak; David F Smith; Richard D Cummings; Xuezheng Song
Journal:  Bioconjug Chem       Date:  2009-07-22       Impact factor: 4.774

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.